RocuroniumNeuromuscular blocker for anaesthesia;aminosteroid CAS# 143558-00-3 |
- A-867744
Catalog No.:BCC1324
CAS No.:1000279-69-5
- Rocuronium Bromide
Catalog No.:BCC1068
CAS No.:119302-91-9
- Rivastigmine
Catalog No.:BCC1900
CAS No.:123441-03-2
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 143558-00-3 | SDF | Download SDF |
| PubChem ID | 441290 | Appearance | Powder |
| Formula | C32H53N2O4+ | M.Wt | 529.77 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO | ||
| Chemical Name | [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17R)-3-hydroxy-10,13-dimethyl-2-morpholin-4-yl-16-(1-prop-2-enylpyrrolidin-1-ium-1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate | ||
| SMILES | CC(=O)OC1C(CC2C1(CCC3C2CCC4C3(CC(C(C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C | ||
| Standard InChIKey | YXRDKMPIGHSVRX-OOJCLDBCSA-N | ||
| Standard InChI | InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Rocuronium is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia.
IC50 value:
Target: References: | |||||
Rocuronium Dilution Calculator
Rocuronium Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 1.8876 mL | 9.4381 mL | 18.8761 mL | 37.7522 mL | 47.1903 mL |
| 5 mM | 0.3775 mL | 1.8876 mL | 3.7752 mL | 7.5504 mL | 9.4381 mL |
| 10 mM | 0.1888 mL | 0.9438 mL | 1.8876 mL | 3.7752 mL | 4.719 mL |
| 50 mM | 0.0378 mL | 0.1888 mL | 0.3775 mL | 0.755 mL | 0.9438 mL |
| 100 mM | 0.0189 mL | 0.0944 mL | 0.1888 mL | 0.3775 mL | 0.4719 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Rocuronium is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
- L 012 sodium salt
Catalog No.:BCC6362
CAS No.:143556-24-5
- XMD17-109
Catalog No.:BCC2061
CAS No.:1435488-37-1
- Shancigusin I
Catalog No.:BCN8272
CAS No.:1435488-35-9
- (4S,5R)-3-(tert-Butoxycarbonyl)-2,2-dimethyl-4-phenyloxazolidine-5-carboxylic acid
Catalog No.:BCN8364
CAS No.:143527-70-2
- 3-Acetoxy-24-hydroxydammara-20,25-diene
Catalog No.:BCN1569
CAS No.:143519-04-4
- Dammarenediol II
Catalog No.:BCN6240
CAS No.:14351-29-2
- Emtricitabine
Catalog No.:BCC3774
CAS No.:143491-57-0
- LOE 908 hydrochloride
Catalog No.:BCC7327
CAS No.:143482-60-4
- 5,8-Dihydroxypsoralen
Catalog No.:BCC8104
CAS No.:14348-23-3
- Cnidilin
Catalog No.:BCN2731
CAS No.:14348-22-2
- Poriol
Catalog No.:BCN6816
CAS No.:14348-16-4
- (Arg)9 peptide
Catalog No.:BCC5336
CAS No.:143413-47-2
- Virgatic acid
Catalog No.:BCN6744
CAS No.:14356-51-5
- Diprenorphine
Catalog No.:BCC5954
CAS No.:14357-78-9
- H-DL-Asp(OMe)-OMe.HCl
Catalog No.:BCC2901
CAS No.:14358-33-9
- A 419259 trihydrochloride
Catalog No.:BCC4308
CAS No.:1435934-25-0
- Cyclo(Leu-Leu)
Catalog No.:BCN2433
CAS No.:1436-27-7
- 5-Hydroxy-2-(4-methoxyphenyl)-8,8-dimethyl-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxypyrano[2,3-h]chromen-4-one
Catalog No.:BCC8807
CAS No.:143601-07-4
- Curculigoside B
Catalog No.:BCN7939
CAS No.:143601-09-6
- 3-(4-Chlorobutyl)indole-5-carbonitrile
Catalog No.:BCC8589
CAS No.:143612-79-7
- (2R,3S)-3-Phenylisoserine ethyl ester
Catalog No.:BCC8388
CAS No.:143615-00-3
- Diacetoxy-6-gingerdiol
Catalog No.:BCN3339
CAS No.:143615-75-2
- Elacridar
Catalog No.:BCC1546
CAS No.:143664-11-3
- G-Protein antagonist peptide
Catalog No.:BCC7206
CAS No.:143675-79-0
Rocuronium-induced neuromuscular block and sugammadex in pediatric patient with duchenne muscular dystrophy: A case Report.[Pubmed:28353578]
Medicine (Baltimore). 2017 Mar;96(13):e6456.
INTRODUCTION: Anesthetic management of patients with Duchenne muscular dystrophy (DMD) is complicated because these patients are more sensitive to nondepolarizing neuromuscular blocking agents (NMBAs) and are vulnerable to postoperative complications, such as postoperative residual curarization and respiratory failure. Sugammadex is a new reversal agent for aminosteroidal NMBAs, but its safety in children is controversial. CLINICAL FEATURES: An 11-year-old boy with DMD underwent general anesthesia for a percutaneous nephrolithotomy. We used Rocuronium bromide and sugammadex to reverse the deep neuromuscular block. Reversal of neuromuscular block was done 15 minutes after administration of 2 mg/kg of sugammadex. The patient's recovery from anesthesia was uneventful, and he was discharged to the postoperative recovery ward. CONCLUSION: A delayed recovery was achieved, but no adverse events were observed, such as recurarization or hypersensitivity to sugammadex. We report safe use of 2 mg/kg of sugammadex to reverse a deep neuromuscular block in a child with DMD.
Reversal with sugammadex for rocuronium-induced deep neuromuscular block after pretreatment of magnesium sulfate in rabbits.[Pubmed:28367292]
Korean J Anesthesiol. 2017 Apr;70(2):203-208.
BACKGROUND: Magnesium sulfate (MgSO4) has been used in the treatment of pre-eclampsia, hypertension and arrhythmia. Magnesium enhances the neuromuscular block of Rocuronium. This study has been conducted to evaluate the reversal efficacy of sugammadex from deep Rocuronium-induced neuromuscular block (NMB) during consistent pretreatment of MgSO4 in rabbits. METHODS: Twenty-eight rabbits were randomly assigned to four groups, a control group or study groups (50% MgSO4 150-200 mg/kg and 25 mg/kg/h IV), and received Rocuronium 0.6 mg/kg. When post-tetanic count 1-2 appeared, sugammadex 2, 4, and 8 mg/kg was administered in the 2-mg group, control and 4-mg group, and 8-mg group, respectively. The recovery course after reversal of sugammadex administration was evaluated in each group. RESULTS: The mean serum concentration of magnesium was maintained at more than 2 mmol/L in the study groups, and the total dose of MgSO4 was more than 590 mg. The reversal effect of sugammadex on Rocuronium-induced NMB in pretreated MgSO4 was not different from that in the group without MgSO4. The recovery time to train-of-four ratio 0.9 after sugammadex administration in the 2-mg group was longer than in the other groups (P < 0.001); there were no other significant differences among the groups. CONCLUSIONS: The reversal of sugammadex from a deep Rocuronium-induced NMB during large pretreatment of MgSO4 was not affected. However, we should consider that the reversal effect of sugammadex varied depending on the dose.
Neuronal Effects of Sugammadex in combination with Rocuronium or Vecuronium.[Pubmed:28367082]
Int J Med Sci. 2017 Feb 23;14(3):224-230.
Rocuronium (ROC) and Vecuronium (VEC) are the most currently used steroidal non-depolarizing neuromuscular blocking (MNB) agents. Sugammadex (SUG) rapidly reverses steroidal NMB agents after anaesthesia. The present study was conducted in order to evaluate neuronal effects of SUG alone and in combination with both ROC and VEC. Using MTT, CASP-3 activity and Western-blot we determined the toxicity of SUG, ROC or VEC in neurons in primary culture. SUG induces apoptosis/necrosis in neurons in primary culture and increases cytochrome C (CytC), apoptosis-inducing factor (AIF), Smac/Diablo and Caspase 3 (CASP-3) protein expression. Our results also demonstrated that both ROC and VEC prevent these SUG effects. The protective role of both ROC and VEC could be explained by the fact that SUG encapsulates NMB drugs. In BBB impaired conditions it would be desirable to control SUG doses to prevent the excess of free SUG in plasma that may induce neuronal damage. A balance between SUG, ROC or VEC would be necessary to prevent the risk of cell damage.
Recurrent Laryngeal Nerve Monitoring and Rocuronium: A Selective Sugammadex Reversal Protocol.[Pubmed:28349321]
World J Surg. 2017 Sep;41(9):2298-2303.
BACKGROUND: The use of neuromuscular blocking agents may affect intraoperative neuromonitoring during thyroid surgery. A selective neuromuscular recovery protocol was evaluated in a retrospective cohort study during human thyroid neural monitoring surgery. METHODS: One hundred and twenty-five consecutive patients undergoing thyroidectomy with intraoperative neuromonitoring followed a selective neuromuscular block recovery protocol-single intubating dose of Rocuronium followed by sugammadex if needed at the first vagal stimulation (V1). RESULTS: Data from 120 of 125 patients could be analysed. Fifteen (12.5%) patients needed sugammadex reversal to obtain an EMG response at the first vagal stimulation (V1). In the remaining 105 patients, spontaneous recovery of Rocuronium-induced neuromuscular block was sufficient for a successful first vagal stimulation (V1). CONCLUSIONS: In patients undergoing thyroid surgery, routine reversal of Rocuronium block with sugammadex is not mandatory for reliable intraoperative neuromonitoring. A selective neuromuscular block recovery approach may be a valuable and more cost-efficient alternative to routine reversal.
